Drugs / Influenza Virus Vaccine, Monovalent A/H3N2v A/Minnesota/11/2010 NYMC X-203
last change Feb 2018 re-read 2 minutes ago

Influenza Virus Vaccine, Monovalent A/H3N2v A/Minnesota/11/2010 NYMC X-203

Vaccine

Developed for
influenza
Investigated by
National Institute of Allergy and Infectious Diseases (NIAID)

Trials 1 · a red edge is where a trial was stopped

2017201820192020202120222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT02921997 Nov 2016 → Mar 2017 avian influenza, swine influenza National Institute of Allergy and Infectious Diseases (NIAID) Completed No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as Influenza Virus Vaccine, Monovalent A/H3N2v A/Minnesota/11/2010 NYMC X-203 ClinicalTrials.gov intervention name — accepted as the source's own label NCT02921997
Modality Vaccine “Inactivated monovalent subvirion H3N2v vaccineNCT02921997